Artrya Limited Secures FDA Clearance for Salix® Coronary Anatomy

Artrya Limited ( (AU:AYA) ) has shared an update.

Artrya Limited has received US FDA 510(k) clearance for its Salix® Coronary Anatomy, a non-invasive tool that provides a rapid assessment of coronary artery disease. This clearance allows Artrya to commercialize in the US market, where it has already established strategic agreements with several hospital groups. The launch of Salix® Coronary Anatomy marks a significant advancement in coronary artery disease diagnostics, promising to improve patient outcomes and reduce healthcare costs. The company plans to leverage insights gained from this process to expedite future product clearances, expanding its market presence and offering new diagnostic capabilities.

More about Artrya Limited

Artrya Limited is an applied artificial intelligence healthcare company based in Perth, Australia. Founded in 2018, the company focuses on improving the diagnosis of coronary heart disease and developing a comprehensive overview of at-risk patients through deep-learning algorithms. Artrya was listed on the Australian Securities Exchange in 2021.

YTD Price Performance: 54.72%

Average Trading Volume: 208,500

Technical Sentiment Signal: Sell

For an in-depth examination of AYA stock, go to TipRanks’ Stock Analysis page.